PB1832: Inflammation induced coagulation in acute myeloid leukemia
Аутори
Mitrović Ajtić, OliveraĐikić, Dragoslava
Suvajdžić-Vuković, Nada
Mitrović, Mirjana
Subotički, Tijana
Vukotić, Milica
Dragojević, Teodora
Diklić, Miloš
Pantić, Nikola
Čokić, Vladan
Конференцијски прилог (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Background: Patients with acute myeloid leukemia (AML) have an increased risk of thrombotic complications in the range of 4.2 - 5.2%.
Aims: Our hypothesis is that inflammation is responsible for deterioration of coagulation in AML.
Methods: Quantification of neutrophil extracellular traps (NETs) from peripheral blood of patients with AML by measurement of circulating cell-free DNA (cfDNA) and myeloperoxidase (MPO) activity. Inflammatory cytokines, coagulation factors and chemokines are measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry in peripheral blood, while fibrinolytic activity with fluorescent tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) assays.
Results: The pro-inflammatory cytokines IL-1β and TNF-α were significantly increased in AML, but not the chemokines IL-8 and MCP-1. NETs were increased in the peripheral blood of patients with AML (p<0.05) as measured by cfDNA and MPO activity. Regarding coagulation, factor VI...II (p<0.05) and adhesion molecule P-selectin (p<0.001) were increased in plasma. Fibrinolytic activity was 3-fold decreased in the plasma of patients with AML (p<0.01) as measured by tPA. In contrast, uPA levels were increased in patients with AML (p<0.05). Tissue factor (CD142+) inflammatory microparticles derived from monocytes (CD14+: 5.1±0.6, p<0.001), activated monocytes (CD14+/CD16+: 2.89±0.4%, p<0.05) and circulating endothelial cells (CD31+/CD144+: 4.08±0.5%, p<0.05) were increased in AML compared to healthy controls.
Summary/Conclusion: Chronic inflammation is present in AML in parallel with reduced fibrinolysis and increased coagulation provoking the risk of thrombosis. A panel of the applied inflammatory/ procoagulant biomarkers can be used as a predictor of thrombosis in AML.
Извор:
HemaSphere - EHA2023 Hybrid Congress Abstract Book, 2023, 7, S3, 68019.6f-Издавач:
- Wolters Kluwer Health, Inc.
Институција/група
Institut za medicinska istraživanjaTY - CONF AU - Mitrović Ajtić, Olivera AU - Đikić, Dragoslava AU - Suvajdžić-Vuković, Nada AU - Mitrović, Mirjana AU - Subotički, Tijana AU - Vukotić, Milica AU - Dragojević, Teodora AU - Diklić, Miloš AU - Pantić, Nikola AU - Čokić, Vladan PY - 2023 UR - http://rimi.imi.bg.ac.rs/handle/123456789/1425 AB - Background: Patients with acute myeloid leukemia (AML) have an increased risk of thrombotic complications in the range of 4.2 - 5.2%. Aims: Our hypothesis is that inflammation is responsible for deterioration of coagulation in AML. Methods: Quantification of neutrophil extracellular traps (NETs) from peripheral blood of patients with AML by measurement of circulating cell-free DNA (cfDNA) and myeloperoxidase (MPO) activity. Inflammatory cytokines, coagulation factors and chemokines are measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry in peripheral blood, while fibrinolytic activity with fluorescent tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) assays. Results: The pro-inflammatory cytokines IL-1β and TNF-α were significantly increased in AML, but not the chemokines IL-8 and MCP-1. NETs were increased in the peripheral blood of patients with AML (p<0.05) as measured by cfDNA and MPO activity. Regarding coagulation, factor VIII (p<0.05) and adhesion molecule P-selectin (p<0.001) were increased in plasma. Fibrinolytic activity was 3-fold decreased in the plasma of patients with AML (p<0.01) as measured by tPA. In contrast, uPA levels were increased in patients with AML (p<0.05). Tissue factor (CD142+) inflammatory microparticles derived from monocytes (CD14+: 5.1±0.6, p<0.001), activated monocytes (CD14+/CD16+: 2.89±0.4%, p<0.05) and circulating endothelial cells (CD31+/CD144+: 4.08±0.5%, p<0.05) were increased in AML compared to healthy controls. Summary/Conclusion: Chronic inflammation is present in AML in parallel with reduced fibrinolysis and increased coagulation provoking the risk of thrombosis. A panel of the applied inflammatory/ procoagulant biomarkers can be used as a predictor of thrombosis in AML. PB - Wolters Kluwer Health, Inc. C3 - HemaSphere - EHA2023 Hybrid Congress Abstract Book T1 - PB1832: Inflammation induced coagulation in acute myeloid leukemia IS - S3 SP - 68019.6f VL - 7 DO - 10.1097/01.HS9.0000974172.68019.6f ER -
@conference{ author = "Mitrović Ajtić, Olivera and Đikić, Dragoslava and Suvajdžić-Vuković, Nada and Mitrović, Mirjana and Subotički, Tijana and Vukotić, Milica and Dragojević, Teodora and Diklić, Miloš and Pantić, Nikola and Čokić, Vladan", year = "2023", abstract = "Background: Patients with acute myeloid leukemia (AML) have an increased risk of thrombotic complications in the range of 4.2 - 5.2%. Aims: Our hypothesis is that inflammation is responsible for deterioration of coagulation in AML. Methods: Quantification of neutrophil extracellular traps (NETs) from peripheral blood of patients with AML by measurement of circulating cell-free DNA (cfDNA) and myeloperoxidase (MPO) activity. Inflammatory cytokines, coagulation factors and chemokines are measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry in peripheral blood, while fibrinolytic activity with fluorescent tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) assays. Results: The pro-inflammatory cytokines IL-1β and TNF-α were significantly increased in AML, but not the chemokines IL-8 and MCP-1. NETs were increased in the peripheral blood of patients with AML (p<0.05) as measured by cfDNA and MPO activity. Regarding coagulation, factor VIII (p<0.05) and adhesion molecule P-selectin (p<0.001) were increased in plasma. Fibrinolytic activity was 3-fold decreased in the plasma of patients with AML (p<0.01) as measured by tPA. In contrast, uPA levels were increased in patients with AML (p<0.05). Tissue factor (CD142+) inflammatory microparticles derived from monocytes (CD14+: 5.1±0.6, p<0.001), activated monocytes (CD14+/CD16+: 2.89±0.4%, p<0.05) and circulating endothelial cells (CD31+/CD144+: 4.08±0.5%, p<0.05) were increased in AML compared to healthy controls. Summary/Conclusion: Chronic inflammation is present in AML in parallel with reduced fibrinolysis and increased coagulation provoking the risk of thrombosis. A panel of the applied inflammatory/ procoagulant biomarkers can be used as a predictor of thrombosis in AML.", publisher = "Wolters Kluwer Health, Inc.", journal = "HemaSphere - EHA2023 Hybrid Congress Abstract Book", title = "PB1832: Inflammation induced coagulation in acute myeloid leukemia", number = "S3", pages = "68019.6f", volume = "7", doi = "10.1097/01.HS9.0000974172.68019.6f" }
Mitrović Ajtić, O., Đikić, D., Suvajdžić-Vuković, N., Mitrović, M., Subotički, T., Vukotić, M., Dragojević, T., Diklić, M., Pantić, N.,& Čokić, V.. (2023). PB1832: Inflammation induced coagulation in acute myeloid leukemia. in HemaSphere - EHA2023 Hybrid Congress Abstract Book Wolters Kluwer Health, Inc.., 7(S3), 68019.6f. https://doi.org/10.1097/01.HS9.0000974172.68019.6f
Mitrović Ajtić O, Đikić D, Suvajdžić-Vuković N, Mitrović M, Subotički T, Vukotić M, Dragojević T, Diklić M, Pantić N, Čokić V. PB1832: Inflammation induced coagulation in acute myeloid leukemia. in HemaSphere - EHA2023 Hybrid Congress Abstract Book. 2023;7(S3):68019.6f. doi:10.1097/01.HS9.0000974172.68019.6f .
Mitrović Ajtić, Olivera, Đikić, Dragoslava, Suvajdžić-Vuković, Nada, Mitrović, Mirjana, Subotički, Tijana, Vukotić, Milica, Dragojević, Teodora, Diklić, Miloš, Pantić, Nikola, Čokić, Vladan, "PB1832: Inflammation induced coagulation in acute myeloid leukemia" in HemaSphere - EHA2023 Hybrid Congress Abstract Book, 7, no. S3 (2023):68019.6f, https://doi.org/10.1097/01.HS9.0000974172.68019.6f . .